Status:
COMPLETED
Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The prevalence of Sickle Cell Associated Nephropathy (SCAN) is increasing and is a growing concern. Microalbuminuria is detected in the early onset of SCAN. Noteworthy, as in diabetic nephropathy, hyp...
Detailed Description
This is a non randomized prospective multicentered study testing the effect of RAS treatment with a wash out period at the end of the study. Enrollment and informed consent will be performed in three...
Eligibility Criteria
Inclusion
- Homozygous sickle cell disease
- \> 18 years
- Patient with social insurance
- Albuminuria/ urinary creatinin \> 10 mg/mmol creatinin (at 2 different times) and MDRD \> 140 ml/min/1.73m2.
- Written inform consent
Exclusion
- Hemoglobin SC or S-betathalassemia disease
- Patient currently treated with: lithium, aspirin, antihypertensive drugs, non steroid-antiinflammatory drugs.
- Pregnancy
- Woman without contraception
- Transfusion within the last 3 months
- Intolerance to RAS inhibitors
- Treatment with RAS in the last month
- Patient with Congenital galactosemia or a malabsorption of glucose or lactase deficiency
- Treatment with hydroxyurea began or changed in the last 3 months
- Infection with HIV or C hepatitis
- Angio-edema
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01195818
Start Date
September 1 2010
End Date
September 1 2014
Last Update
June 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de la Drépanocytose, Service de Médecine Interne. Hôpital Tenon, 4 Rue de la Chine
Paris, Paris, France, 75020